Phesi Analysis Shows Breast Cancer Was the Most Extensively Studied Disease Area in 2021
Published on:
Data also show COVID-19 to be second most studied disease area, and further highlight patient enrollment challenges.
Phesi Inc. today released the results of its global analysis of all clinical trials conducted in 2021. The data show that breast cancer was the most studied disease area, followed by COVID-19. Overall, oncology dominated the top five, which also included non-small cell lung cancer, solid tumors and multiple myeloma.
Within breast cancer clinical development 25,000 investigator sites have been solely dedicated to recruiting patients since 2017; this trend was not impacted by COVID-19; this includes pharma and academic studies and the same investigator sites involved in multiple trials. This means an average of 5,000-7,000 people are continually working on breast cancer clinical trials, with Phesi’s model showing this is likely to continue.
